https://scholars.lib.ntu.edu.tw/handle/123456789/484032
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | WEN-YING LIN | en_US |
dc.contributor.author | CHIH-PENG LIN | en_US |
dc.contributor.author | CHIH-HUNG HSU | en_US |
dc.contributor.author | Lee, Ying Hui | en_US |
dc.contributor.author | Lin, Yi Ting | en_US |
dc.contributor.author | Hsu, Meng Chi | en_US |
dc.contributor.author | YU-YUN SHAO | en_US |
dc.creator | Shao, Yu Yun;Hsu, Meng Chi;Lin, Yi Ting;Lee, Ying Hui;Hsu, Chih Hung;Lin, Chih Peng;Lin, Wen Ying | - |
dc.date.accessioned | 2020-04-09T09:43:48Z | - |
dc.date.available | 2020-04-09T09:43:48Z | - |
dc.date.issued | 2017-09-26 | - |
dc.identifier.issn | 00070920 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/484032 | - |
dc.description.abstract | © 2017 Cancer Research UK. All rights reserved. Background:Totally implantable vascular access device (TIVAD)-related complications interfere in the anticancer treatment and increase medical expenses. We examined whether the implantation side of central line TIVADs is associated with the occurrence of thrombotic or occlusion events.Methods:We enrolled patients with cancer who required central line TIVADs and randomised them to receive the TIVAD implantation on either the left or right side. The primary endpoint was the occurrence of catheter-related thrombotic or occlusion events.Results:We randomised 240 patients, of which 235 received TIVAD implantation according to the protocol. In the per-protocol cohort, 117 and 118 patients received implantation on the left and right sides, respectively. Catheter-related thrombotic or occlusion events occurred in 9 (4%) patients, accounting for 0.065 events per 1000 catheter-days. Between the patients with left-and right-sided implantations, the occurrence rates (P=0.333) and the time from catheter implantation to the occurrence of thrombotic or occlusion events (P=0.328) were both similar. In the multivariate analysis, the side of implantation remained unassociated with the occurrence of thrombotic or occlusion events.Conclusions:The side of central line TIVAD implantation was not associated with the occurrence of catheter-related thrombotic or occlusion events in patients with cancer. | en_US |
dc.relation.ispartof | British Journal of Cancer | en_US |
dc.subject | cancer | catheter-related infection | central catheter | thrombosis | en_US |
dc.subject | cancer; catheter-related infection; central catheter; thrombosis | en_US |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | D dimer; fibrinogen; antineoplastic agent; adult; artery puncture; Article; cancer patient; candidiasis; catheter infection; catheter occlusion; catheter removal; catheter sheath; catheter thrombosis; central venous catheterization; cohort analysis; controlled study; female; fibrinogen blood level; follow up; Gram negative infection; Gram positive infection; human; implantable port system; intraluminal thrombosis; left sided totally implantable vascular access device implantation; lymphoma; major clinical study; male; middle aged; observational study; priority journal; randomized controlled trial; right sided totally implantable vascular access device implantation; Staphylococcus epidermidis; Staphylococcus infection; superior cava vein; totally implantable vascular access device; treatment outcome; vascular access device; vascular guide wire; vein puncture; vein thrombosis; adverse effects; aged; Catheter Obstruction; Catheter-Related Infections; catheterization; device failure; Neoplasms; procedures; vascular access device; Venous Thrombosis; Aged; Antineoplastic Agents; Catheter Obstruction; Catheter-Related Infections; Catheterization, Peripheral; Equipment Failure; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasms; Vascular Access Devices; Venous Thrombosis | - |
dc.title | Right or left? Side selection for a totally implantable vascular access device: A randomised observational study | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1038/bjc.2017.264 | - |
dc.identifier.pmid | 28787431 | - |
dc.identifier.scopus | 2-s2.0-85029899801 | - |
dc.identifier.url | https://api.elsevier.com/content/abstract/scopus_id/85029899801 | - |
dc.relation.journalvolume | 117 | en_US |
dc.relation.journalissue | 7 | en_US |
dc.relation.pageend | 937 | en_US |
item.fulltext | no fulltext | - |
item.openairetype | journal article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Anesthesiology-NTUCC | - |
crisitem.author.dept | Anesthesiology-NTUH | - |
crisitem.author.dept | Anesthesiology | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Medical Oncology-NTUCC | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Cancer Administration and Coordination Center | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.orcid | 0000-0001-5714-6260 | - |
crisitem.author.orcid | 0000-0003-2928-3203 | - |
crisitem.author.orcid | 0000-0003-0495-973X | - |
crisitem.author.orcid | 0000-0001-7334-1912 | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。